Literature DB >> 6289230

[Bacteriological, pharmacological and clinical comparison between amoxycillin and ceftriaxone in the treatment of 300 purulent meningitis ].

M Cadoz, F Denis, T Guerma, M Prince-David, I Diop Mar.   

Abstract

Two series of patients suffering purulent meningitis were treated: one (137 patients) with amoxycillin (200 mg/kg/day) by 4 intramuscular injections each day, the other with ceftriaxone (163 patients)/42 mg/Kg/day IM by intramuscular injections each day in the first 23 patients and then only one injection by day in the 140 other patients. Bacteriologically the superiority of CFTRX appears the whole studied strains: MIC of CFTRX are four times lower than those of AMOX for pneumococci, ten times lower for H. influenzae, hundred time lower for meningococci. Amongst the add strains the percentage of resistance to AMOX reaches 64 and only 7 to CFTRX. Pharmacologically, after a same dose of 50mg/kg the peak concentrations in CSF has the same level: CFTRX: 6.8 micrograms/ml, AMOX: 6 micrograms/ml. CSF levels remain efficient for 2 hours with AMOX and for 24 hours with CFTRX. The therapeutic index (mean antibiotic concentration in CSF/mean MIC of the strains) is higher with CFTRX than with AMOX (X 4 for pneumococci, X 15 for H. influenzae, X 100 for meningococci). Clinical results are better with CFTRX than with AMOX in each of the aetiological groups except meningococcal meningitis but the only significative difference concerns pneumococcal meningitis. Clinical tolerance of the two treatments was good. However 2 neonates treated with CFTRX has a severe eczematous erythrodermia and 8 other patients treated with CFTRX had diarrhoea due to elimination of the sensitive flora.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289230

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  9 in total

Review 1.  Neonatal erythroderma: differential diagnosis and management of the "red baby".

Authors:  P H Hoeger; J I Harper
Journal:  Arch Dis Child       Date:  1998-08       Impact factor: 3.791

2.  The potential uses of ceftriaxone.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

Review 3.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Short course single daily ceftriaxone monotherapy for acute bacterial meningitis in children: results of a Swiss multicenter study. Part I: Clinical results.

Authors:  E Martin; P Hohl; T Guggi; F H Kayser; M Fernex
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults.

Authors:  K Marhoum el Filali; M Noun; A Chakib; M Zahraoui; H Himmich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

Review 7.  Rationale for optimal dosing of beta-lactam antibiotics in therapy for bacterial meningitis.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol       Date:  1984-12       Impact factor: 3.267

8.  Comparison of ceftriaxone and ampicillin plus chloramphenicol for the therapy of acute bacterial meningitis.

Authors:  J P Bryan; H Rocha; H R da Silva; A Taveres; M A Sande; W M Scheld
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

Review 9.  Proposal for a 6-step approach for differential diagnosis of neonatal erythroderma.

Authors:  E Cuperus; A Bygum; L Boeckmann; C Bodemer; M C Bolling; M Caproni; A Diociaiuti; S Emmert; J Fischer; A Gostynski; S Guez; M E van Gijn; K Hannulla-Jouppi; C Has; A Hernández-Martín; A E Martinez; J Mazereeuw-Hautier; M Medvecz; I Neri; V Sigurdsson; K Suessmuth; H Traupe; V Oji; S G M A Pasmans
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-15       Impact factor: 9.228

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.